1262007-41-9

Upstream product

• 1262008-23-0 methyl 2-(6-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetate 
• 1262008-05-8 2-(5-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1H-indol-3-yl)ethanol 
• 957208-65-0 4-(chloromethyl)-1-cyclopentyl-2-(trifluoromethyl)benzene 
• 154-02-9 5-hydroxytryptophol 

Downstream Products

• 1262009-08-4 (S)-2-(6-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid 

Relevant academic research and scientific papers

Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor

Modulators of S1P1 have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P1 chemotypes were designed and optimize

MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to certain compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.